This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $184,528 to Case Western Reserve University to conduct research on the role of the vaginal microbiome and antibody-bound bacteria in human papillomavirus (HPV) infection and cervical dysplasia. The key objectives are to characterize the abundance, species/genera, and functional profiles of antibody-bound and unbound vaginal bacteria in women with and...
This $189,540 Project Grant award, funded by the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program, supports a study to elucidate racial and ethnic differences in the functional effects of the vaginal microbiome on ovarian cancer. The study, conducted by Duke University, will apply an untargeted metabolomics approach to compare metabolite profiles of cervicovaginal fluid samples from 120 ovarian cancer patients across Black, Hispanic, and White racial/ethnic groups....
This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
This $717,285 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund a large-scale investigation of the vaginal ecosystem and its potential role in preeclampsia. The project aims to uncover the microbial, metabolomic, and immune properties of the vaginal microbiome that may indicate, predispose to, or contribute to the development of preeclampsia, a serious...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), will fund a pilot study to evaluate the associations of pre- and post-chemotherapy and -radiotherapy gut microbiome profiles with breast cancer recurrence and mortality. The $175,000 award will support the use of shotgun metagenome sequencing on 110 post-treatment stool samples from the Vietnam Breast Cancer Study, as well as an investigation of the impact of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $226,204 to the University of Maryland, Baltimore to investigate the vaginal microbiome and immune response factors that contribute to the spontaneous clearance of Chlamydia trachomatis (CT) infections in women. The key objectives are to: (1) evaluate species- and strain-specific vaginal bacterial growth rates, (2)...
This $409,612 project grant awarded by the National Institute of Justice (under CFDA 16.741 - DNA Backlog Reduction Program) aims to develop a method for associating sexual assault evidence with suspects using the vaginal and penile microbiome. Key objectives include: Analyzing the microbiome of 70 individuals, including 20 married couples, before and after sexual contact to investigate microbiome transfer. This will involve collecting vaginal and labial swabs from female participants....
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $700,350 to Case Western Reserve University to define the neovaginal microbiome after gender-affirming vaginoplasty surgery. The study aims to characterize the microbiome composition of the neovagina and investigate its relationship to genital inflammation and clinical outcomes in transgender women. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Topaz Biosciences, Inc. to discover and optimize novel endolysins that can selectively target Gardnerella vaginalis, the primary bacterial species associated with bacterial vaginosis (BV). The goal is to develop improved endolysins that are more active, thermostable, and pH tolerant than...